about
Phase I and pharmacokinetic study of irofulven administered weekly or biweekly in advanced solid tumor patients.A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors.A phase I and pharmacokinetic study of irofulven and capecitabine administered every 2 weeks in patients with advanced solid tumors.Preclinical and clinical development of novel agents that target the protein kinase C family.ProLindac (AP5346): a review of the development of an HPMA DACH platinum Polymer Therapeutic.Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes.OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models.Fsn0503h antibody-mediated blockade of cathepsin S as a potential therapeutic strategy for the treatment of solid tumors.OTX008, a selective small-molecule inhibitor of galectin-1, downregulates cancer cell proliferation, invasion and tumour angiogenesis.Epithelial-to-mesenchymal transition and resistance to ingenol 3-angelate, a novel protein kinase C modulator, in colon cancer cells.Repression of cell cycle-related proteins by oxaliplatin but not cisplatin in human colon cancer cells.Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells.Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies.Enhanced antitumor activity of irofulven in combination with 5-fluorouracil and cisplatin in human colon and ovarian carcinoma cells.
P50
Q33360955-D4E007D6-022A-452B-838F-3791D0EB47D8Q33371139-2794ECC7-473B-4A30-8EFB-DF5643C89B26Q33375872-3FCE006B-AEE5-4EE6-84A8-B53BE676F0C0Q36557306-27A89CD8-0783-46C2-B205-33592B343CC3Q37578054-9D705F77-BB27-4ED4-855E-16632AE9FDADQ38409231-528F33E8-825E-4DD1-AC05-01B9B7E0111BQ38759279-EE91F50A-A57A-4E23-8ED9-823927F5EDA8Q38935561-1E46DD56-749A-4529-8BA0-CEC868A4D50EQ38973814-B4AB3C18-93DF-4E53-9035-33DB5C164C96Q39856424-4435782B-A2AB-4AD2-A003-8D737448DFA5Q40229877-C58DE0C3-19B4-4A0C-A699-D070EB7D0B9AQ40390076-9E4338EA-422C-4050-AE4D-F292BA154F24Q40571471-2BCBD523-111C-4C38-AA2F-58FBD10F3C7BQ40628100-347A0F52-0FD5-4BE6-91DB-0F2983570B7C
P50
description
onderzoeker
@nl
name
Esteban Cvitkovic
@ast
Esteban Cvitkovic
@en
Esteban Cvitkovic
@es
Esteban Cvitkovic
@nl
Esteban Cvitkovic
@sl
type
label
Esteban Cvitkovic
@ast
Esteban Cvitkovic
@en
Esteban Cvitkovic
@es
Esteban Cvitkovic
@nl
Esteban Cvitkovic
@sl
prefLabel
Esteban Cvitkovic
@ast
Esteban Cvitkovic
@en
Esteban Cvitkovic
@es
Esteban Cvitkovic
@nl
Esteban Cvitkovic
@sl
P106
P21
P31
P569
2000-01-01T00:00:00Z